Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.
Quick Facts
Reference Sizes
1.5 mg
Storage
No approved consumer storage standard exists for this presentation; follow the lot-specific COA and validated stability data
Solubility
Aqueous injectable solution; available as Symlin pen
Best-Effort Research Profile
Pramlintide is a synthetic analog of human amylin, a hormone co-secreted with insulin by pancreatic beta cells. The FDA approved pramlintide (Symlin) in 2005 as an adjunct to mealtime insulin therapy in adults with type 1 or type 2 diabetes, working by slowing gastric emptying, suppressing glucagon secretion, and promoting satiety. It is administered by injection at mealtimes, separately from insulin.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Research Profile
Half-Life
~48 minutes
Onset
Rapid, meal-related effect
Administration Routes (Research)
Subcutaneous (SC)
Reported Research Effects
Slows gastric emptying
Suppresses glucagon secretion
Promotes satiety
Reported Research Side Effects
Human safety, pharmacokinetics, and interaction data are incomplete
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Route-Specific Research Protocols
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
Label / guidelineHuman studyCommunity onlyPreclinical onlyNot established
Subcutaneous (SC)Label / guideline
Type 1 diabetes: start 15 mcg before major meals and titrate to 30-60 mcg; type 2 diabetes: start 60 mcg and increase to 120 mcg
Frequency / timing
Before major meals
Duration / setting
Ongoing
Technique
SC
Evidence
Regulatory label
Context: SYMLINPEN prescribing information
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: Use only in the cited label or guideline context; route, formulation, indication, and patient-specific limits still apply.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
Research Interactions
Flagged Avoid / Caution Combinations (Research)
Gastroparesis
Hypoglycemia unawareness
Insulin use without label-directed dose adjustment
Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.
Research Notes
Mealtime insulin must be reduced as directed when initiating pramlintide because severe hypoglycemia can occur.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.